| 配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2025年度: 1,170千円 (直接経費: 900千円、間接経費: 270千円)
2024年度: 1,690千円 (直接経費: 1,300千円、間接経費: 390千円)
2023年度: 1,820千円 (直接経費: 1,400千円、間接経費: 420千円)
|
|---|
| 研究実績の概要 |
2023年3月31日現在で363例を登録した。
このうち206例登録時点の退院時までのデータについて第88回日本循環器学会学術集会で発表した（Actual status of wearable cardioverter defibrillator use in patients with acute myocardial infarction -A report from SING AMI registry-）
この発表の結果と結論は以下の通りである。
Results: Among 206 patients with AMI (ages 70.9 ± 12.8 years, male 74.8 percent), 13 (6.3%) had WCD indication. Although physicians considered WCD indication for 9 patients, misidentified indication in 7: VF occurrence within 48h after AMI onset in 2, NSVT in 2, and unknown reason in 3. Of 20 patients with WCD indication or misidentified indication, 19 patients did not receive informed consent about WCD because physicians missed indication in 11, poor general condition in 2, expected poor compliance in 2, and ICD implantation before discharge in 1, unknown reason in 4. One patient disagreed with taking WCD because of the high cost and resistance to WCD. As a result, WCD was prescribed in no patients.
Conclusions: Data from the SING AMI registry showed that using WCD after AMI was underused although WCD was indicated in 6% of patients with AMI undergoing primary PCI. Rate of misidentification for WCD indication was not rare (8.7%), even at facilities with capable of WCD.
|
